156 related articles for article (PubMed ID: 20432183)
1. Hematologic malignancies-sixth European congress. 26-28 February 2010, Cannes, France .
Buske C
IDrugs; 2010 May; 13(5):300-3. PubMed ID: 20432183
[TBL] [Abstract][Full Text] [Related]
2. Use of bortezomib in B-cell non-Hodgkin's lymphoma.
Wang M; Zhou Y; Zhang L; Nguyen CA; Romaguera J
Expert Rev Anticancer Ther; 2006 Jul; 6(7):983-91. PubMed ID: 16831071
[TBL] [Abstract][Full Text] [Related]
3. Lymphoma study group of JCOG.
Tsukasaki K; Tobinai K; Hotta T; Shimoyama M
Jpn J Clin Oncol; 2012 Feb; 42(2):85-95. PubMed ID: 22147803
[TBL] [Abstract][Full Text] [Related]
4. Recent advances in the treatment of non-Hodgkin's lymphomas.
Abramson JS; Zelenetz AD
J Natl Compr Canc Netw; 2013 May; 11(5 Suppl):671-5. PubMed ID: 23704240
[TBL] [Abstract][Full Text] [Related]
5. A summer of hematologic science. Highlights from the 45th Annual Meeting of the American Society of Clinical Oncology, the 14th Congress of the European Hematology Association, and the 2009 Pan Pacific Lymphoma Conference.
Cheson BD; Ashforth E
Clin Adv Hematol Oncol; 2009 Sep; 7(9 Suppl 15):1-22; quiz 23-4. PubMed ID: 20102012
[No Abstract] [Full Text] [Related]
6. Bortezomib: a proteasome inhibitor with an evolving role in select subtypes of B-cell non-Hodgkin's lymphoma.
Koprivnikar JL; Cheson BD
Future Oncol; 2012 Apr; 8(4):359-71. PubMed ID: 22515439
[TBL] [Abstract][Full Text] [Related]
7. Phase II trial of piperazinedione in Hodgkin's disease, non-Hodgkin's lymphoma, and multiple myeloma: a Southwest Oncology Group study.
Jones SE; Tucker WG; Haut A; Tranum BL; Vaughn C; Chase EM; Durie BG
Cancer Treat Rep; 1977 Dec; 61(9):1617-21. PubMed ID: 340032
[TBL] [Abstract][Full Text] [Related]
8. Safety, tolerability, and preliminary activity of CUDC-907, a first-in-class, oral, dual inhibitor of HDAC and PI3K, in patients with relapsed or refractory lymphoma or multiple myeloma: an open-label, dose-escalation, phase 1 trial.
Younes A; Berdeja JG; Patel MR; Flinn I; Gerecitano JF; Neelapu SS; Kelly KR; Copeland AR; Akins A; Clancy MS; Gong L; Wang J; Ma A; Viner JL; Oki Y
Lancet Oncol; 2016 May; 17(5):622-31. PubMed ID: 27049457
[TBL] [Abstract][Full Text] [Related]
9. 2nd International Congress on Leukemia, Lymphoma and Myeloma.
Arat M; Ozsan GH; Yenerel MN; Cetin M; Ozcan M
Expert Rev Hematol; 2009 Oct; 2(5):509-12. PubMed ID: 21083016
[TBL] [Abstract][Full Text] [Related]
10. Lenalidomide in lymphomas and chronic lymphocytic leukemia.
Wiernik PH
Expert Opin Pharmacother; 2013 Mar; 14(4):475-88. PubMed ID: 23356486
[TBL] [Abstract][Full Text] [Related]
11. CAL-101: a phosphatidylinositol-3-kinase p110-delta inhibitor for the treatment of lymphoid malignancies.
Castillo JJ; Furman M; Winer ES
Expert Opin Investig Drugs; 2012 Jan; 21(1):15-22. PubMed ID: 22112004
[TBL] [Abstract][Full Text] [Related]
12. Lymphoid malignancies: a decade and a half of dramatic improvements in outcome.
Zelenetz AD
Clin Lymphoma Myeloma; 2008 Aug; 8 Suppl 4():S126-7. PubMed ID: 18952542
[No Abstract] [Full Text] [Related]
13. Novel and Expanded Oncology Drug Approvals of 2016-PART 2: New Options in the Management of Hematologic Malignancies.
Knepper TC; Saller J; Walko CM
Oncology (Williston Park); 2017 Feb; 31(2):138-46. PubMed ID: 28205194
[TBL] [Abstract][Full Text] [Related]
14. Developing new drugs for the treatment of lymphoma.
O'Connor OA
Eur J Haematol Suppl; 2005 Jul; (66):150-8. PubMed ID: 16007885
[TBL] [Abstract][Full Text] [Related]
15. American Society of Hematology--51st annual meeting & exposition. Part 1.
Shumoogam J; Beecher N
IDrugs; 2010 Feb; 13(2):57-9. PubMed ID: 20127549
[TBL] [Abstract][Full Text] [Related]
16. Ubiquitin Drug Discovery & Diagnostics 2009 - First Annual Conference.
Marblestone JG
IDrugs; 2009 Dec; 12(12):750-3. PubMed ID: 19943215
[TBL] [Abstract][Full Text] [Related]
17. Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies.
O'Connor OA; Heaney ML; Schwartz L; Richardson S; Willim R; MacGregor-Cortelli B; Curly T; Moskowitz C; Portlock C; Horwitz S; Zelenetz AD; Frankel S; Richon V; Marks P; Kelly WK
J Clin Oncol; 2006 Jan; 24(1):166-73. PubMed ID: 16330674
[TBL] [Abstract][Full Text] [Related]
18. [Clinical development of a proteasome inhibitor, bortezomib, for the treatment of myeloma and lymphoma].
Tobinai K
Rinsho Ketsueki; 2007 Jun; 48(6):451-7. PubMed ID: 17633092
[No Abstract] [Full Text] [Related]
19. Lenalidomide for the treatment of B-cell malignancies.
Chanan-Khan AA; Cheson BD
J Clin Oncol; 2008 Mar; 26(9):1544-52. PubMed ID: 18285605
[TBL] [Abstract][Full Text] [Related]
20. Bortezomib: efficacy comparisons in solid tumors and hematologic malignancies.
Caravita T; de Fabritiis P; Palumbo A; Amadori S; Boccadoro M
Nat Clin Pract Oncol; 2006 Jul; 3(7):374-87. PubMed ID: 16826218
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
